2-氨基-2-去甲菠烷羧酸

生物活性靶点体外研究体内研究 2-氨基-2-去甲菠烷羧酸试剂级价格

2-氨基-2-去甲菠烷羧酸

CAS号:20448-79-7
英文名:2-AMINO-2-NORBORNANECARBOXYLIC ACID
中文名:2-氨基-2-去甲菠烷羧酸
CBNumber:CB1384309
分子式:C8H13NO2
分子量:155.19
MOL File:20448-79-7.mol

2-氨基-2-去甲菠烷羧酸化学性质

熔点 :>300 °C(lit.)
沸点 :295.5±23.0 °C(Predicted)
密度 :1.256±0.06 g/cm3(Predicted)
储存条件 :Keep in dark place,Sealed in dry,Room Temperature
溶解度 :Aqueous Acid (Slightly)
形态 :Solid
酸度系数(pKa) :2.58±0.20(Predicted)
颜色 :White
水溶解性 :Soluble to 100 mM in water
CAS 数据库 :20448-79-7(CAS DataBase Reference)

安全信息

WGK Germany :3

2-氨基-2-去甲菠烷羧酸性质、用途与生产工艺

生物活性 BCH (2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, LAT1-IN-1) 是一种选择性的、竞争性的 system L amino acid transporter 1 (LAT1)的抑制剂。BCH (LAT1-IN-1) 可在癌细胞中诱导凋亡。
靶点
Target Value
LAT1
()

体外研究

LAT1-IN-1 (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner.
LAT1-IN-1 (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that LAT1-IN-1 induces cell cycle arrest at G1 phase.
LAT1-IN-1 (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased.

Cell Proliferation Assay

Cell Line:	KYSE30 and KYSE150 esophageal cancer cells
Concentration:	1 mM, 3 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, or 100 mM
Incubation Time:	3 days
Result:	Cell proliferation was suppressed in a dose-dependent manner.

Cell Cycle Analysis

Cell Line:	KYSE30 and KYSE150 cells
Concentration:	30 mM
Incubation Time:	24 and 48 hours
Result:	Cell cycle arrest.

Western Blot Analysis

Cell Line:	KYSE30 and KYSE150 cells
Concentration:	30 mM
Incubation Time:	0 hour, 0.5 hour, 1 hour, 3 hours, 6 hours, 24 hours
Result:	Phosphorylation of 4E-BP1 and p70S6K was decreased. The amount of mTOR, 4E-BP1, and p70S6K proteins was slightly decreased.

体内研究

LAT1-IN-1 (200 mg/kg; intravenous injection; daily; for 14 days; male BALB/c nude mice) treatment significantly delays tumor growth and decreases glucose metabolism, indicating that LAT1 inhibition potentially suppresses esophageal cancer growth in vivo.

Animal Model:	Male BALB/c nude mice (5-week-old) with KYSE150 cells
Dosage:	200 mg/kg
Administration:	Intravenous injection; daily; for 14 days
Result:	Significantly delayed tumor growth and decreased glucose metabolism.